Compare Aspen Aerogels Inc (ASPN) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs BioNTech SE - ADR — how do they compare? Aspen Aerogels Inc trades at $5.25 (market cap $427.65M), while BioNTech SE - ADR trades at $90.89 (market cap $23.14B). The key difference: BioNTech SE - ADR is far larger — about 54.1× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| ASPN | BNTX | |
|---|---|---|
Market Cap | $427.65M | $23.14B |
Sector | Technology | Health |
52-Week High | $8.82 | $119.34 |
52-Week Low | $2.57 | $83.89 |
Enterprise Value | $382.60M | $6.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $5.16, down 1.53% on the day, with a bearish technical signal despite oversold RSI readings. The company reported a Q1 2026 loss of $0.28 per share, missing estimates, but revenue beat expectations. Recent news includes a 2025 Supplier of the Year award from General Motors and the staged restart of its East Providence facility. Financials show significant net losses but improving cash flow trends into 2026.
Outlook remains challenging with persistent losses and negative margins, though analyst consensus is strongly bullish (83% buy ratings). Key risks include execution on facility restarts and EV demand volatility. The stock offers high-risk growth potential if operational improvements and electrification trends accelerate profitability.
BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.
The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
